Results 191 to 200 of about 76,815 (259)

A deep learning framework for lesion-level treatment response prediction in hodgkin lymphoma using PET/CT tensor radiomics. [PDF]

EJNMMI Phys
Jajroudi M, Jamalirad H, Enferadi M, Roshanravan V, Emami F, Geramifar P, Eslami S.   +6 more
europepmc   +1 more source

A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B‐Cell Lymphoma

American Journal of Hematology, Volume 101, Issue 9, Page 2177-2189, September 2026.
ABSTRACT Mosunetuzumab plus polatuzumab vedotin has shown promising activity versus rituximab plus polatuzumab vedotin (R‐Pola) in patients with relapsed/refractory (R/R) large B‐cell lymphoma (LBCL; NCT03671018). We present results from the Phase II randomized cohort, evaluating subcutaneous mosunetuzumab plus polatuzumab vedotin (Mosun‐Pola), with ...
Julio C. Chavez, Mariana Bastos‐Oreiro, Catherine Diefenbach, Izidore S. Lossos, Nirav Shah, Sarit Assouline, Adam J. Olszewski, Seema Naik, Nilanjan Ghosh, Song Pham, Michael C. Wei, Connie Batlevi, Iris To, Wahib Ead, Sneha Makadia, Elicia Penuel, Jing Jing, Lihua E. Budde   +17 more
wiley   +1 more source

Psychological distress and quality of life in patients with indolent non-Hodgkin lymphoma. [PDF]

Support Care Cancer
Kuiper JW, Custers JAE, Kleinjan A, Verpoorte-Botden IPG, van Amstel FKP.   +4 more
europepmc   +1 more source

The IL‐10/IL‐6 Ratio and the Risk Score: Two Cytokines‐Based Predictors for Malignancy‐Associated Hemophagocytic Lymphohistiocytosis in Adults (M‐HLHa)

American Journal of Hematology, Volume 101, Issue 9, Page 2214-2224, September 2026.
ABSTRACT The predictive value of cytokines (CK) for malignancy‐associated adult hemophagocytic lymphohistiocytosis (M‐HLHa) remains uncertain. We evaluated a cytokine‐based Risk Score (RS) and the IL‐10/IL‐6 Ratio to predict M‐HLHa. Adult patients (n = 112) from the French HLH cohort (NCT02113917) with complete data for nine key HLH related CK measured
Coralie Bloch, Stephanie Chhun, Nanthara Sritharan, Marine Gil, Raphael Lhote, Marouane Boubaya, Olivier Lambotte, David Launay, Claire Larroche, Estibaliz Lazaro, Francois Liffermann, Marc Michel, Jean‐Marie Michot, Pierre Morel, Louis Terriou, Geoffrey Urbansk, Jean‐Francois Viallard, Morgane Cheminant, Felipe Suarez, Yves Lepelletier, Geneviève de Saint Basile, Olivier Hermine, the French HLH Study Group, Coralie Bloch, Jean Philippe Jais, Francois Liffermann, Pierre Morel, Morgane Cheminant, Felipe Suarez, Olivier Hermine, Fabrice Bonnet, Pascal Godemer, Damaj Gandhi, Olivier Fain, Olivier Lambotte, David Launay, Louis Terriou, Claire Larroche, Estibaliz Lazaro, Jean‐Francois Viallard, Francois Liffermann, Olivier Lortholary, Marc Michel, Jean‐Marie Michot, Pierre Morel, Frederic Pene, Antoinette Perlat, Geoffrey Urbanski   +47 more
wiley   +1 more source

Inflammatory Signaling and Endothelial Activation Drive Thrombosis in Hodgkin and Non-Hodgkin Lymphoma. [PDF]

Cells
Živković E, Mitrović-Ajtić O, Ivanović J, Djikić D, Subotički T, Diklić M, Vukotić M, Dragojević T, Antić D, Čokić VP.   +9 more
europepmc   +1 more source

Clinical Predictors of Response in Chronic Graft‐Versus‐Host Disease: Results From the “Predicting the Quality of Response to Specific Treatments (PQRST)” Trial

American Journal of Hematology, Volume 101, Issue 9, Page 2280-2287, September 2026.
ABSTRACT Despite significant progress in chronic GVHD therapies, challenges remain in understanding pleomorphic phenotypes and varying responses to treatment. The aim of this study was to identify predictors of treatment response. We conducted a prospective, observational cohort study of patients beginning first‐, second‐, or third‐line systemic ...
Betty K. Hamilton, Lynn Onstad, Paul A. Carpenter, Joseph Pidala, George Chen, Corey Cutler, Najla El Jurdi, Nosha Farhadfar, Mark Juckett, Carrie L. Kitko, Catherine J. Lee, Stephanie J. Lee   +11 more
wiley   +1 more source

Case Report: Anti-PL-12 Antisynthetase syndrome complicated by natural killer/T cell non-Hodgkin's lymphoma. [PDF]

Front Immunol
Li K, Liang ME, Liu Y, Guo QY, Xu K.
europepmc   +1 more source

Payload‐Based Clinical Pharmacology Review of Approved Antibody–Drug Conjugates: Commonalities and Considerations for Streamlined Development

Clinical Pharmacology &Therapeutics, Volume 120, Issue 3, Page 614-638, September 2026.
Antibody–drug conjugates (ADCs) combine the specificity of an antibody with the potency of a cytotoxic drug. Thirteen ADCs, utilizing seven unique cytotoxic payloads and targeting 11 distinct antigens, are currently approved by the US Food and Drug Administration as of June 2025, representing a rapidly growing and highly promising class of anticancer ...
Sijie Lu, Qingqing Xiao, Lixuan Qian, Siyuan Sun, Zhu Zhou, Michael Z. Liao, Chunze Li   +6 more
wiley   +1 more source

Evolution of therapeutic paradigms in Hodgkin lymphoma: from "cure-oriented" to "functional cure". [PDF]

Front Oncol
Chen C, Guo W, Song X, Wan X, Li Z, Wang H, Bai O.   +6 more
europepmc   +1 more source

Diffuse Large B-Cell Lymphoma of the Ethmoid Sinus With Orbital Invasion: A Case Report. [PDF]

Cureus
Boualam Y, Sbai A, Benfadil D, Lachkar A.   +3 more
europepmc   +1 more source